Progesterone and breast cancer

Women's Health

Volumn 4, Issue 2, 2008, Pages 151-162

  Lange, Carol A ^a   Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; Estrogen receptor; Growth factor; Hormone replacement therapy; Progesterone; Progesterone receptor; Protein kinase; Steroid hormone

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; INSULIN RECEPTOR SUBSTRATE 2; MEDROXYPROGESTERONE; MEGESTROL; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEU DIFFERENTIATION FACTOR; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN C FOS; PROTEIN KINASE P60; PROTEIN P160; PROTEIN P21; SOMATOMEDIN C; STAT PROTEIN; TAMOXIFEN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TRANSCRIPTION FACTOR SNF; UNINDEXED DRUG; WNT1 PROTEIN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL CYCLE REGULATION; DRUG MEGADOSE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; NONHUMAN; POSTMENOPAUSE; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; UPREGULATION;

ANIMALS; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HAPLORHINI; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROGESTERONE; PROGESTINS; RATS; RECEPTORS, PROGESTERONE;

EID: 41949128999     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.2.151     Document Type: Review

References (93)

1. Hewitt SC, Korach KS: Progesterone action and responses in the αERKO mouse. Steroids 65(10-11), 551-557 (2000).
2. Feng Y, Manka D, Wagner KU, Khan SA: Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. Proc. Natl Acad. Sci. USA 104 (37), 14718-14723 (2007).
3. Mulac-Jericevic B, Conneely OM: Reproductive tissue selective actions of progesterone receptors. Reproduction 128 (2), 139-146 (2004).
4. Haslam SZ, Counterman LJ, Nummy KA: Effects of epidermal growth factor, estrogen, and progestin on DNA synthesis in mammary cells in vivo are determined by the developmental state of the gland. J. Cell. Physiol. 155 (1), 72-78 (1993).
5. Ruan W, Monaco ME, Kleinberg DL: Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 146 (3), 1170-1178 (2005).
6. Ankrapp DP, Bennett JM, Hastain SZ: Role of epidermal growth factor in the acquisition of ovarian steroid hormone responsiveness in the normal mouse mammary gland. J. Cell. Physiol. 174 (2), 251-260 (1998).
7. Robinson GW, Hennighausen L, Johnson PF: Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev. 14 (8), 889-894 (2000).
8. Haslam SZ, Woodward TL: Host microenvironment in breast cancer development: Epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res. 5(4), 208-215 (2003).
9. Li Y, Rosen JM: Stem/progenitor cells in mouse mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 10(1), 17-24 (2005).
10. Wenger CR, Clark GM: S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res. Treat 51(3), 255-265 (1998).
11. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ: Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146(8), 3577-3588 (2005).
12. Chlebowski RT, Hendrix SL, Langer RD et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289(24), 3243-3253 (2003).
13. Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev. 18(4), 502-519 (1997).
14. Haslam SZ, Osuch JR, Raafat AM, Hofseth LJ: Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J Mammary Gland Biol. Neoplasia 7(1), 93-105 (2002).
15. Kraus WL, Montano MM, Katzenellenbogen BS: Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promoters. Mol. Endocrinol. 7(12), 1603-1616 (1993).
16. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB: New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J. Biol. Chem. 277(31), 27793-27800 (2002).
17. Richer JK, Jacobsen BM. Manning NG, Abel MG, Wolf DM, Horwitz KB: Differential gene regulation by the two prugesterone receptor isoforms in human breast cancer Cells. J. Biol. Chem. 277(7), 5209-5218 (2002).
18. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM: Defective mammary gland morphogenesis in mice lacking the progesterone receplor B isoform. Proc. Natl Acad. Sci. USA 100(17). 9744-9749 (2003).
19. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289 (5485). 1751-1754 (2000).
20. Wei LL, Norris BM, Baker CJ: An N-terminally truncated third progesterone receptor protein, PR(C), forms heterodimers with PR(B) but interferes in PR(B)-DNA binding. J. Steroid Biochem. Mol. Biol. 62(4), 287-297 (1997).
21. Condon JC, Hardy DB, Kovaric K, Mendelson CR: Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function. Mol. Endocrinol. 20(4), 764-775 (2006).
22. Pratt WB, Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp7O-based chaperone machinery. Exp. Biol. Med. (Maywood) 228(2), 111-133 (2003).
23. Moore MR, Zhou JL, Blankenship KA, Strobl JS, Edwards DP, Gentry RN: A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene. J. Steroid Biochem. Mol. Biol. 62(4), 243-252 (1997).
24. Chalbos D, Chambon M, Allhaud G, Rochefort H: Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J. Biol. Chem. 262 (21), 9923-9926 (1987).
25. Krusekopf S, Chauchereau A, Milgrom E, Henderson D, Cato AC: Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. J. Steroid Biochem. Mol. Biol. 40(1-3), 239-245 (1991).
26. Lange CA, Richer JK, Shen T, Horwitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J. Biol. Chem. 273(47), 31308-31316 (1998).
27. Richer JK, Lange CA, Wierman AM et al.: Progesterone receptor variants found in breast cells repress transcription by wild-type receptors. Breast Cancer Res. Treat. 48(3), 231-241 (1998).
28. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB: Progesterone regulates transcription of the p21 (WAF 1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273(17), 10696-10701 (1998).
29. Cui X, Lazard Z, Zhang P, Hopp TA, Lee AV: Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 22 (44), 6937-6941 (2003).
30. Groshong SD, Owen GI, Grimison B et al.: Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kip 1). Mol. Endocrinol. 11 (11), 1593-1607 (1997).
31. Tseng L, Tang M, Wang Z, Mazella J: Progesterone receptor (hPR) upregulates the fibronectin promoter activity in human decidual fibroblasts. DNA Cell Biol. 22(10), 633-640 (2003).
32. Proietti C, Salatino M, Rosemblit C et al.: Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol. Cell Biol. 25 (12), 4826-4840 (2005).
33. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB: Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J. Biol. Chem. 273(47), 31317-31326 (1998).
34. Boonyaratanakornkit V, Scott MP, Ribon V et al.: Progesterone receptor contains a proline-rich motif that directly Interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell. 8(2), 269-280 (2001).
35. Migliaccio A, Piccolo D, Castoria G et al.: Activation of the Src/ p21 ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17(7), 2008-2018 (1998).
36. Saitoh M, Ohmichi M, Takahashi K et al.: Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-κB cascade in human breast cancer cells. Endocrinology 146(11), 4917-4925 (2005).
37. Shupnik MA: Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23(48), 7979-7989 (2004).
38. Migliaccio A, Castoria G, Di Domenico M, Ballare C, Beato M, Auricchio F: The progesterone receptor/estradiol receptor association and the progestin-triggered S-phase entry. Ernst Schering Res. Found. Workshop (52), 39-54 (2005).
39. Migliaccio A, Castoria G, Di Domenico M et al.: Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J. 19(20), 5406-5417 (2000).
40. Skildum A, Faivre E, Lange CA: Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol. Endocrinol. 19(2), 327-339 (2005).
41. Faivre E, Lange C: Progesterone receptors upregulate Wnt-1 to induce EGFR transactivation and c-Src-dependent sustained activation of Erk1/2 MAP kinase in breast cancer cells. Mol. Cell Biol. 27(2), 466-480 (2006).
42. Pierson-Mullany LK, Lange CA: Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol. Cell Biol. 24 (24), 10542-10557 (2004).
43. Faivre E, Daniel AR, Hillard C, Lange CA. Progesterone receptor rapid signaling mediates Ser345 phosphorylation and tethering to Sp1 transcription factors. Mol. Endocrinol. doi: 10.1210/me.2007-0437 (2008) (Epub ahead of print).
44. Labriola L, Salatino M, Projetti CJ et al.: Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol. Cell Biol. 23(3), 1095-1111 (2003).
45. Qiu M, Lange CA: MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J. Steroid Biochem. Mol. Biol. 85, 147-157 (2003).
46. Santen R, Jeng MH, Wang JP et al.: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J. Steroid Biochem. Mol. Biol. 79(1-5), 115-125 (2001).
47. Gee JM, Robertson JF, Ellis IO, Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95(4), 247-254 (2001).
48. Wilson GR, Cramer A, Welman A et al.: Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br. J. Cancer 95 (10), 1410-1414 (2006).
49. Aupperlee MD, Haslam SZ: Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology 148 (5), 2290-2300 (2007).
50. Kariagina A, Aupperlee MD, Haslam SZ: Progesterone receptor isoforms and proliferation in the rat mammary gland during development. Endocrinology 148(6), 2723-2736 (2007).
51. Navarrete MA, Maier CM, Faizoni R et al.: Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res. 7(3), R306-R313 (2005).
52. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L: Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am. J. Obstet Gynecol. 176 (1 Pt 1), 123-128 (1997).
53. Stute P, Wood CE, Kaplan JR, Cline JM: Cyclic changes in the mammary gland of cynomolgus macaques. Fertil. Steril. 82(Suppl. 3), 1160-1170 (2004).
54. Dabrosin C: Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res. Treat 80(2), 193-198 (2003).
55. Haslam SZ: Experimental mouse model of hormonal therapy effects on the postmenopausal mammary gland. Breast Dis. 24, 71-78 (2005).
56. Soderqvist G: Effects of sex steroids on proliferation in normal mammary tissue. Ann. Med. 30(6), 511-524 (1998).
57. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84(12), 4559-4565 (1999).
58. Anderson GL, Limacher M, Assaf AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004).
59. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382), 419-427 (2003).
60. Alkarain A, Jordan R, Slingerland J: p27 deregulation in breast cancer: prognostic significance and implications for therapy. J. Mammary Gland Biol. Neoplasia 9(1). 67-80 (2004).
61. Steeg PS, Zhou Q: Cyclins and breast cancer. Breast Cancer Res. Treat 52(1-3), 17-28 (1998).
62. Kumar S, Walia V, Ray M, Elble RC: p53 in breast cancer: mutation and countermeasures. Front. Biosci. 12, 4168-4178 (2007).
63. Narayanan R, Adigun AA, Edwards DP, Weigel NL: Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol. Cell Biol. 25(1), 264-277 (2005).
64. Narayanan R, Edwards DP, Weigel NL: Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol. Cell Biol. 25(8), 2885-2898 (2005).
65. Pierson-Mullany LK, Skildum A, Faivre E, Lange CA: Cross-talk between growth factor and progesterone receptor signaling pathways: implications for breast cancer cell growth. Breast Dis. 18, 21-31 (2003).
66. McGowan EM, Russell AJ, Boonyaratanakornkit V et al.: Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res. 67(18), 8942-8951 (2007).
67. Rose-Hellekant TA, Sandgren EP: Transforming growth factor α- and c-myc-induced mammary carcinogenesis in transgenic mice. Oncogene 19(8), 1092-1096 (2000).
68. Ma Y, Katiyar P, Jones LP et al.: The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol. 20(1), 14-34 (2006).
69. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brea1 -mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804), 1467-1470 (2006).
70. Lange CA, Gioeli D, Hammes SR, Marker PC: Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu. Rev. Physiol. 69, 171-199 (2007).
71. Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA: Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 72(2), 188-201 (2007).
72. Sben T, Horwitz KB, Lange CA: Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell Biol. 21(18), 6122-6131 (2001).
73. Daniel AR, Faivre EJ, Lange CA: Phosphorylation-dependent antagonism of sumoylation de-represses progesterone receptor action in breast cancer cells. Mol. Endocrinol. 21(122), 2890-906 (2007).
74. McGowan EM, Clarke CL: Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol. Endocrinol. 13(10), 1657-1671 (1999).
75. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB: Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol. Endocrinol 19(3), 574-587 (2005).
76. Graham JD, Yeates C, Balleine RL et al.: Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 55(21), 5063-5068 (1995).
77. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB: Expression profiling of human breast cancers and gene regulation by progesterone receptors. J. Mammary Gland Biol. Neoplasia 8(3), 257-268 (2003).
78. Hissom JR, Moore MR: Progestin effects on growth in the human breast cancer eell line T-47D - possible therapeutic implications. Biochem. Biophys. Res. Commun., 145(2), 706-711 (1987).
79. Musgrove EA, Lee CS, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell Biol. 11 (10), 5032-5043 (1991).
80. Lange CA, Richer JK, Horwitz KB: Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol. Endocrinol. 13(6), 829-836 (1999).
81. Lange CA: Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol. Endocrinol. 18 (2), 269-278 (2004).
82. Moore MR, Spence JB, Kiningham KK, Dillon JL: Progestin inhibition of cell death in human breast cancer cell lines. J Steroid Biochem. Mol. Biol. 98(4-5), 218-227 (2006).
83. Sartorius CA, Harvell DM, Shen T, Horwitz KB: Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res. 65(21), 9779-9788 (2005).
84. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D: Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br. J. Cancer 95(9), 1220-1228 (2006).
85. Woodward TL, Lu H, Haslam SZ: Laminin inhibits estrogen action in human breast cancer cells. Endocrinology 141(8), 2814-2821 (2000).
86. Ravdin PM, Cronin KA, Howlader N et al.: The decrease in breast-cancer incidence in 2003 in the United States. N Engl. J. Med. 356(16), 1670-1674 (2007).
87. Robbins AS, Clarke CA: Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J. Clin. Oncol. 25 (23), 3437-3439 (2007).
88. Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J: Progestins and breast cancer. J Steroid Biochem. Mol. Biol. 65(1-6), 225-235 (1998).
89. Kennedy BJ: Hormonal therapies in breast cancer. Semin. Oncol. 1(2), 119-130 (1974).
90. Allan GF, Palmer E, Musto A, Lai MT, Clancy J, Palmer S: Molecular properties and preclinical pharmacology of JNJ-1250132, a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro. Steroids 71 (7), 578-584 (2006).
91. Perrault D, Eisenhauer EA, Pritchard KI et al.: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin. Oncol. 14(10), 2709-2712 (1996).
92. Grunberg SM, Weiss MH, Russell CA et al.: Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 24(8), 727-733 (2006).
93. Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S: Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 35(2), 214-218 (1999).